









Markets
/
Stocks
/
nasdaq-mnmd
/

Mind Medicine (MindMed) Inc

MNMD

12.100USD

-0.190-1.55%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

917.22MMarket Cap

LossP/E TTM



Mind Medicine (MindMed) Inc

12.100

-0.190-1.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mind Medicine (MindMed) Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mind Medicine (MindMed) Inc's Score

Industry at a Glance

Industry Ranking

220 / 501

Overall Ranking

391 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.909

Target Price

+75.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mind Medicine (MindMed) Inc Highlights

StrengthsRisks

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -9.78, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 42.43M shares, decreasing 12.21% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.11K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Mind Medicine (MindMed) Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.27, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -9.78, which is -90.90% below the recent high of -0.89 and -18.60% above the recent low of -11.60.

Score

Industry at a Glance

Previous score

6.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 220/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.60, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Mind Medicine (MindMed) Inc is 21.00, with a high of 55.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.909

Target Price

+75.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Mind Medicine (MindMed) Inc

MNMD

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.88, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 14.36 and the support level at 11.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.39

Change

1.49

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.117

Neutral

RSI(14)

50.026

Neutral

STOCH(KDJ)(9,3,3)

44.406

Sell

ATR(14)

1.016

High Vlolatility

CCI(14)

0.231

Neutral

Williams %R

74.564

Sell

TRIX(12,20)

0.688

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

13.132

Sell

MA10

12.841

Sell

MA20

12.688

Sell

MA50

11.132

Buy

MA100

9.828

Buy

MA200

8.334

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 55.77%, representing a quarter-over-quarter decrease of 0.37%. The largest institutional shareholder is The Vanguard, holding a total of 1.80M shares, representing 2.37% of shares outstanding, with 6.33% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.22M

+0.33%

Commodore Capital LP

5.00M

+10.50%

Blackstone Alternative Asset Management, L.P.

3.59M

Marshall Wace LLP

3.42M

+31.93%

Driehaus Capital Management, LLC

3.09M

-7.72%

Deep Track Capital LP

2.50M

Octagon Capital Advisors LP

2.13M

-29.42%

State Street Investment Management (US)

1.81M

-1.97%

The Vanguard Group, Inc.

Star Investors

1.80M

+2.70%

Geode Capital Management, L.L.C.

1.73M

+4.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 3.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.